Correction: Dolutegravir/Abacavir/Lamivudine versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study

Authors :: Benoît, Trottier
Jordan E, Lake
Ken, Logue
Cynthia, Brinson
Lizette, Santiago
Clare, Brennan
Justin A, Koteff
Brian, Wynne
Judy, Hopking
Catherine, Granier
Michael, Aboud
Source :: Antiviral Therapy. 22:459-460
Publication Year :: 2016
Publisher :: SAGE Publications, 2016.

Tools